促性腺激素释放激素激动剂、睾丸切除术与心血管疾病风险:半生态全国人群研究
该半生态研究纳入瑞典前列腺癌数据库3.0中1992-1999年接受促性腺激素释放激素(GnRH)激动剂(6556例)或睾丸切除术(3330例)作为初始治疗的前列腺癌患者,以医疗提供者、诊断时间段和诊断年龄定义的580个实验单元分析GnRH激动剂使用比例与心血管疾病(CVD)风险的关系。结果显示,GnRH激动剂使用比例最高与最低单元间的CVD风险相似(相对风险1.01,95%CI 0.93-1.11),GnRH激动剂与睾丸切除术后的CVD净概率无差异(风险比1.02,95%CI 0.96-1.09)。作者结论认为数据不支持GnRH激动剂相比睾丸切除术增加CVD风险的既往观察。
要点
- GnRH激动剂使用比例最高与最低单元间CVD风险相似(相对风险1.01,95%CI 0.93-1.11)。
- GnRH激动剂与睾丸切除术后的CVD净概率无差异(风险比1.02,95%CI 0.96-1.09)。
- 10年CVD粗概率:GnRH激动剂组0.56(95%CI 0.55-0.57),睾丸切除术组0.52(95%CI 0.50-0.54)。
核心结论
- 数据不支持GnRH激动剂相比睾丸切除术增加CVD风险的既往观察。
研究设计与样本
- 半生态研究,纳入6556例接受GnRH激动剂和3330例接受睾丸切除术作为初始治疗的前列腺癌患者,数据来自瑞典前列腺癌数据库3.0,治疗年份1992-1999。
- 以医疗提供者、诊断时间段和诊断年龄定义580个实验单元,测量各单元中接受GnRH激动剂作为初始治疗的患者比例。
- 比较GnRH激动剂高使用比例单元与低使用比例单元的CVD事件,并分析净概率和粗概率。
主要发现
- GnRH激动剂使用比例最高与最低单元间的CVD风险相似(相对风险1.01,95%CI 0.93-1.11)。
- GnRH激动剂与睾丸切除术后的CVD净概率无差异(风险比1.02,95%CI 0.96-1.09)。
- 10年CVD粗概率:GnRH激动剂组0.56(95%CI 0.55-0.57),睾丸切除术组0.52(95%CI 0.50-0.54)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限性为治疗非随机分配,较年轻、合并症较少且癌症分期较早的男性更可能接受GnRH激动剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In observational studies, men with prostate cancer treated with gonadotropin-releasing hormone (GnRH) agonists had a higher risk of cardiovascular disease (CVD) compared to men who had undergone orchiectomy. However, selection bias may have influenced the difference in risk. OBJECTIVE: To investigate the association of type of androgen deprivation therapy (ADT) with risk of CVD while minimising selection bias. DESIGN, SETTING, AND PARTICIPANTS: Semi-ecologic study of 6556 men who received GnRH agonists and 3330 men who underwent orchiectomy as primary treatment during 1992-1999 in the Prostate Cancer Database Sweden 3.0. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured the proportion of men who received GnRH agonists as primary treatment in 580 experimental units defined by healthcare provider, diagnostic time period, and age at diagnosis. Incident or fatal CVD events in units with high and units with low use of GnRH agonists were compared. Net and crude probabilities were also analysed. RESULTS AND LIMITATIONS: The risk of CVD was similar between units with the highest and units with the lowest proportion of GnRH agonist use (relative risk 1.01, 95% confidence interval [CI] 0.93-1.11). Accordingly, there was no difference in the net probability of CVD after GnRH agonist compared to orchiectomy (hazard ratio 1.02, 95% CI 0.96-1.09). The 10-yr crude probability of CVD was 0.56 (95% CI 0.55-0.57) for men on GnRH agonists and 0.52 (95% CI 0.50-0.54) for men treated with orchiectomy. The main limitation was the nonrandom allocation to treatment, with younger men with lower comorbidity and less advanced cancer more likely to receive GnRH agonists. CONCLUSION: Our data do not support previous observations that GnRH agonists increase the risk of CVD in comparison to orchiectomy. PATIENT SUMMARY: We found a similar risk of cardiovascular disease between medical and surgical treatment as androgen deprivation therapy for prostate cancer.
引用
- Thomsen FB, Sandin F, Garmo H, et al. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. Eur Urol. 2017. PMID: 28711383. doi:10.1016/j.eururo.2017.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。